|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Top Lists |
Insider Trading Graph View |
Insider Watch |
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise" - Peter Lynch ==>> What is insider trading>> |

| Transaction & Date | Reported Date |
Company | Symbol | Insider Relationship |
Shares Traded | Average Price | Total Amount |
Shares Ownership |
Filing |
| 2009-01-06 Sale(C) |
2009-01-07 5:05 pm | GENELABS TECHNOLOGIES INC | SWTX | PFEFFER MATTHEW J (Director) | 10,000 | $1.3 | $13,000 | 0 (Direct) | View |
| 2007-12-04 Purchase |
2007-12-04 8:59 pm | VAXGEN INC | VXGN | PFEFFER MATTHEW J (SENIOR VICE PRESIDENT AND CFO) | 10,000 | $0.46 | $4,600 | 20,000 (Direct) |
View |
| 2007-11-15 Purchase |
2007-11-15 9:32 pm |
VAXGEN INC | VXGN | PFEFFER MATTHEW J (SENIOR VICE PRESIDENT AND CFO) | 10,000 | $0.6 | $6,000 | 10,000 (Direct) |
View |
| Transaction & Date | Reported Date |
Company | Symbol | Insider Relationship |
Shares Traded | Average Price | Total Amount | Shares Ownership |
Filing |
| 2008-04-28 Option Award |
2008-04-30 8:21 pm | MANNKIND CORP | MNKD | PFEFFER MATTHEW J (Corporate VP and CFO) | 4,500 | $0 | $0 | 4,500 (Direct) |
View |
| 2004-07-30 Exercise | 2004-07-30 6:37 pm |
CELL GENESYS INC | CEGE | PFEFFER MATTHEW J (VP & Chief Financial Officer) | 10,000 | $4.125 | $41,250 | 33,114 (Direct) | View |
| 2003-08-01 Other | 2003-08-04 3:45 pm |
CELL GENESYS INC | CEGE | PFEFFER MATTHEW J (V.P. & Chief Financial Officer) | 361 | $8.084 | $2,918 | 22,503 (Direct) |
View |
| Transaction & Date | Reported Date | Exercisable Expiration | Company | Symbol | Insider Relationship | Shares Traded | Conversion Price | Shares Ownership |
Filing |
| 2008-08-13 Option Award |
2008-08-15 8:19 pm | 2009-08-13 2018-08-13 |
MANNKIND CORP | MNKD | PFEFFER MATTHEW J (Corporate VP and CFO) | 40,000 | $3.89 | 40,000 (Direct) | View |
| 2008-06-30 Option Award |
2008-07-02 2:47 pm |
2008-09-30 2018-06-30 |
GENELABS TECHNOLOGIES INC | GNLB | PFEFFER MATTHEW J (Director) | 10,000 | $0.63 | 10,000 (Direct) |
View |
| 2008-04-28 Option Award |
2008-04-30 8:21 pm |
2009-04-21 2018-04-20 |
MANNKIND CORP | MNKD | PFEFFER MATTHEW J (Corporate VP and CFO) | 20,300 | $2.23 | 20,300 (Direct) | View |
| 2007-07-27 Option Award |
2007-07-31 8:09 pm | N/A 2017-07-27 |
GENELABS TECHNOLOGIES INC | GNLB | PFEFFER MATTHEW J (Director) | 20,000 | $1.96 | 20,000 (Direct) | View |
| 2007-02-12 Option Sale | 2007-02-14 9:58 pm |
N/A 2016-03-30 |
VAXGEN INC | VXGN.PK | PFEFFER MATTHEW J (Chief Financial Officer) | 120,000 | $8.58 | 120,000 (Direct) |
View |
| 2007-02-12 Option Award |
2007-02-14 9:58 pm | N/A 2017-02-12 |
VAXGEN INC | VXGN.PK | PFEFFER MATTHEW J (Chief Financial Officer) | 30,000 | $2.23 | 30,000 (Direct) |
View |
| 2007-02-12 Option Award |
2007-02-14 9:58 pm | N/A 2017-02-12 | VAXGEN INC | VXGN.PK | PFEFFER MATTHEW J (Chief Financial Officer) | 290,000 | $2.23 | 290,000 (Direct) | View |
| 2006-03-30 Option Award | 2006-04-03 5:29 pm | 2007-03-30 2017-03-30 | VAXGEN INC | VXGN.PK | PFEFFER MATTHEW J (SR VICE PRESIDENT AND CFO) | 120,000 | $8.58 | 120,000 (Direct) |
View |
| 2005-02-03 Option Award |
2005-02-04 8:08 pm | 2005-02-03 2015-02-03 | CELL GENESYS INC | CEGE | PFEFFER MATTHEW J (VP Finance & CFO) | 42,500 | $6.73 | 42,500 (Direct) |
View |
| 2004-07-30 Exercise |
2004-07-30 6:37 pm | 1999-11-06 2008-11-06 |
CELL GENESYS INC | CEGE | PFEFFER MATTHEW J (VP & Chief Financial Officer) | 10,000 | $4.125 | 191,875 (Direct) | View |
| 2004-02-02 Option Award |
2004-02-04 1:51 pm |
2004-01-01 2014-02-02 | CELL GENESYS INC | CEGE | PFEFFER MATTHEW J (VP & Chief Financial Officer) | 22,500 | $14.04 | 201,875 (Direct) |
View |
|
© 2005-2009 SecForm4.Com All rights reserved. Archives: 2009 2008 2007 2006 2005 2004 ... Fri, 09 Jan 2009 22:19:22 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |